The following information may help to address your question:
More detailed information about the treatment of idiopathic pulmonary hemosiderosis can be accessed through Medscape. Click on the following links to learn more about Treatment & Management and Medications.
The clinical course of idiopathic pulmonary hemosiderosis varies widely. Overall, the prognosis is poor, with a mean survival of 2.5 to 3 years following diagnosis. Death may result from acute massive hemorrhage or from progressive pulmonary insufficiency and right heart failure. Treatment does not appear to greatly improve survival. One study noted the following:
Another study of children with idiopathic pulmonary hemosiderosis found that the presence of antineutrophil cytoplasmic antibodies or other autoantibodies translated to a poor prognosis. Survival in this study, after 17 years, was reported at 80%.